Tenax Therapeutics, Inc. announced the appointment of three medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) to its Scientific Advisory Board for the company’s planned Phase 2 clinical study in the use of levosimendan for patients with PH-HFpEF. The scientific advisory board will be chaired by Stuart Rich, M.D., Professor of Medicine Northwestern University Feinberg School of Medicine and Director, Pulmonary Vascular Disease Program, Bluhm Cardiovascular Institute. Two additional experts will join Dr. Rich as inaugural members of the scientific advisory board: Daniel Burkhoff MD, PhD, Director Heart Failure, Hemodynamics and MCS Research at the Cardiovascular Research Foundation and Adjunct Associate Professor of Medicine, Columbia University, and Sanjiv Shah, MD, Professor of Medicine Director, T1 Center for Cardiovascular Therapeutics, and Director, Northwestern HFpEF Program, Division of Cardiology, Department of Medicine Northwestern University Feinberg School of Medicine. Dr. Rich is Professor of Medicine Northwestern University Feinberg School of Medicine, and Director, Pulmonary Vascular Disease Program Bluhm Cardiovascular Institute. Dr. Burkhoff is Director Heart Failure, Hemodynamics and MCS Research at the Cardiovascular Research Foundation (CRF) and Adjunct Associate Professor of Medicine, Columbia University. Dr. Shah is Professor of Medicine and Director of the T1 Center for Cardiovascular Therapeutics at Northwestern University Feinberg School of Medicine.